Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.56 |
| ▸ | AXL | P30530 | 5/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456935 | 0.95 | KDR (0.57) | KDRAXLPDGFRAFGFR2KIT | |
| SCHEMBL23456797 | 0.94 | MET (0.57) | KDRAXLPDGFRAFGFR2KIT | |
| SCHEMBL23457007 | 0.94 | KDR (0.56) | KDRAXLPDGFRAFGFR2KIT | |
| SCHEMBL23457199 | 0.93 | KDR (0.55) | KDRAXLPDGFRAFGFR2KIT | |
| SCHEMBL23456823 | 0.91 | KDR (0.59) | KDRAXLPDGFRAFGFR2KIT | |
| SCHEMBL23457196 | 0.91 | KDR (0.55) | KDRAXLPDGFRAFGFR2KIT | |
| SCHEMBL23457011 | 0.90 | AXL (0.53) | KDRAXLPDGFRAKITMET | |
| SCHEMBL23456975 | 0.90 | KDR (0.55) | KDRAXLPDGFRAFGFR2KIT | |
| SCHEMBL23457122 | 0.90 | KDR (0.51) | KDRAXLPDGFRAFGFR2KIT | |
| SCHEMBL23458667 | 0.88 | KDR (0.53) | KDRAXLPDGFRAFGFR2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163448-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R | QURIENT CO., LTD. (KR) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163448-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R | CSF1R, CSF3R, FLT3 | KDR 25/4885AXL 4/4885PDGFRA 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.